The Zoetis Equine Story

Always by the Side of Horses and Their Caregivers



HEY CARTY US.

They've carried us for centuries...millennia. On their backs we've conquered our foes, and our fears. On their backs we've made discoveries about our world, and ourselves. They're our therapy, our labor, our companions, our comfort. Because of all they've done for us, we're driven to do what's right for them. To know them better, so we can treat them better. To realize their needs, so they can realize their greatness. To help all horses live their best lives, so they can continue helping us live better **li**ves.

Long Live the Horse.



Always by your side.

When a horse bonds with us, it's a special connection that runs deep.

It comes from the horse knowing that they are following someone who values them. Someone who has taken the time to build a relationship and communicate with them on their level. Someone who has proven they can be trusted and counted on, no matter what.

It takes heartfelt commitment to give horses the right care throughout every life stage and owner lifestyle. It takes time and diligence to meet their physical and emotional needs. It takes patience and knowledge to discover what helps them thrive. And it takes the right partner to help you every step of the way.

Zoetis Equine is by the side of horses and their caregivers every day. Because we know that when horses recognize care and dedication, they return it tenfold. Helping create those infinitely rewarding relationships is what we live for.

HORSE-FIRST COMMITMENT

We relentlessly seek to make what's best for horses and their well-being our first priority in everything we make, do and say.

TRAILBLAZING VISION



We are devoted to advancing the frontier of horse care to make horses' lives better, one discovery at a time.

COMPREHENSIVE CARE

We offer premium products and guidance across the continuum of care and the continuum of a horse's life.

Decades of care.

Our brand's history.

1952

Established The Animal Agriculture division of Pfizer. Renamed Pfizer Animal Health in 1988, which became Zoetis in 2013.

1991

Dormosedan[®] sterile solution (detomidine hydrochloride) received FDA approval, and this game-changing tool for veterinarians remains the #1 vet-trusted equine sedative.¹

2009

Acquired Fort Dodge Animal Health, which brought key brands like West Nile Innovator®, Fluvac Innovator®, Pneumabort–K® 1b, Ketofen®, Quest® Gel and Quest® Plus Gel.

2012

Announced Pfizer's Animal Health business would become a separate company, Zoetis, making us the world's largest animal health company.

2015

Launched Lepto EO Innovator®, a new vaccine to protect against leptospirosis and help reduce the risk of equine recurrent uveitis, abortion and acute renal failure caused by L. pomona.

2013

Celebrated our initial public offering (IPO), becoming the world's leading publicly traded animal health company.

1982

Strongid[®] Paste and Anthelcide[®] EQ Paste entered the market.

2003 Established dedicated R&D headquarters in Kalamazoo, Michigan.

2010

Acquired Synbiotics Corporation, entering animal diagnostics.

FDA approved **EXCEDE**[®] Sterile Suspension as the first safe and effective, long-acting antibiotic formulation licensed for horses. Acquired **Platinum Performance**[®], a leading nutrition-focused animal health business for horses and small animals.

Expanded the Zoetis Equine portfolio to include **Stablelab**[®] stall-side diagnostic blood test to detect and quantify the biomarker serum amyloid A (SAA).

2018

Launched Core EQ Innovator®, the first and only vaccine to protect horses from all five core diseases in one injection, which won the Animal Pharm award for Best New Product for Companion Animals that same year.

Created a standalone Equine business unit totally focused on serving horses, equine veterinarians, horse owners and the equine industry.

Acquired Abaxis, Inc. a leader in diagnostic instruments for veterinary point-of-care services, including **VetScan®** and **iStat® Alinity**.

2021

Acquired portfolio of equine regenerative medicine devices, including **Pro-Stride® APS, Restigen® PRP** and **CenTrate® BMA**.



We're with you every step of the way.

We provide 360 degrees of support for horses and their caregivers. To help you continually build your knowledge, our technical services and product support teams offer ongoing guidance on equine care best practices, disease states and product solutions.

Equine Specialists

A team of highly trained sales professionals fully dedicated to serving equine veterinary customers. From product training to business tools to client support, these Zoetis Equine representatives are always by your side.

Veterinary Medical Information and Product Support (VMIPS) Team

Veterinarians and veterinary technicians with more than 50 years of combined experience, here to answer questions regarding the safety and appropriate use of Zoetis products.

Equine Technical Services Team

Zoetis veterinarians who support veterinary customers with their deep technical knowledge of our products and protocols, combined with their own practical experience as equine practitioners. Contact your Zoetis Equine Specialist for help connecting with an equine technical services veterinarian.

Best-In-Class Customer Service

Our customer service team is here to help you place orders, track deliveries, answer questions about your account and our products and services.

C

Contact for one-on-one support 1-888-963-8471



Providing horse care you can count on.

From diagnostic tools to preventive and acute treatments, we'll be there for you across the continuum of care.

Prevent

VACCINES

Help protect against infectious disease with industry-leading products.

Innovator

The first and only vaccine to help protect against all five potentially fatal core equine diseases in one injection.

Innovator

The #1 equine influenza vaccine on the market.²



DIAGNOSTICS

Provide cutting edge patient care with convenient diagnostic instruments.

In just 10 minutes, using the Stablelab® handheld, stall-side SAA test, veterinarians can detect inflammation caused by infection, screen for infection, and monitor the response to treatment – all without waiting for lab results. The VETSCAN® family of lab instruments (HM5, VS2) and iSTAT® Alinity v are advanced analyzers that deliver real-time, lab-quality results for blood gases, electrolytes, chemistries and hematology using a small quantity of blood.





i-STAT Alinity v

Treat

PHARMACEUTICALS

Industry-leading medications for sedation, pain management, reproduction, and more.

DORMOSEDAN®

(detomidine hydrochloride

Dormosedan Sterile Solution is the #1 vet-trusted equine sedative with the unique benefit of analgesia.¹ **Dormosedan Gel** is the only mild standing sedative of its kind, providing horse owners with a unique tool for routine horse care procedures. See Important Safety Information on back cover.

PARASITICIDES

Select the dewormer targeted to the horse's life stage.

QUEST (moxidectin)

Moxidectin is the experts' treatment of choice against small strongyles including their encysted larvae, and also treats a broad spectrum of other parasites.³

QUESTPLUS (moxidectin/praziquantel) Provides the same benefits as Quest Gel, plus praziquantel to target tapeworms.

REGENERATIVE MEDICINE DEVICES

Heal with horse power utilizing stall-side technology clinically demonstrated to reduce orthopedic pain.4

Our innovative triad of devices process blood or bone marrow aspirate collected from the horse that can be prepared in less than 20 minutes with an autologous protein solution, platelet rich plasma or bone marrow aspirate solution ready for immediate use.





Support

NUTRITION







Trusted antimicrobials for respiratory health.



The first and only FDA-approved antibiotic for horses that offers a full course of therapy in just two doses, making treatment of equine respiratory infections* less stressful for the horse and more convenient for caretakers. *Caused by susceptible strains of Streptococcus equi ssp. zooepidemicus

t s, d	ANTHELCIDE [®] EQ EXAMPLE (oxibendazole)	Recommended for the essential treatment of ascarids in foals at 4–6 months of age and 1 month post– weaning. Also treats large strongyles, pinworms, and threadworms in adult horses.
	STRONGID [*] (pyrantel pamoate)	Recommended for the essential treatment of ascarids in foals at 2–3 months of age. Also effective against large strongyles and pinworms in adult horses.



Veterinary-developed, advanced nutrition for equine health.



Caring for our community.

Zoetis is deeply committed to a healthy and sustainable equine industry. We support veterinary organizations, local and national horse events, and other groups that contribute to the broader equine community.

Additionally, we provide ongoing funding for equine health research, veterinary student scholarships, continuing education, disaster relief for the equine community and much more.

Our commitment to veterinarians and the industry.

CONTINUING EDUCATION





NAREP Together For The Horse



RESEARCH



University of Kentucky Gluck Equine Research Center College of Agriculture, Food, and Environment





WORLD ORGANISATION FOR ANIMAL HEALTH















Trailblazing vision.

As the world's leading animal health company, Zoetis is driven by a purpose to nurture our world and humankind by advancing care for animals. Building on our 70-year history and singular focus on animal health, we're helping horses live better lives one discovery at a time. We offer best-in-class solutions for horse caregivers across the continuum of care and the continuum of a horse's life.

Always by your side, by the numbers.

15

Zoetis veterinarians that support equine veterinary customers



Continuum of Care

Continuum of Life

Continuum of Caregivers

30+ Industry partnerships and sponsorships

14



Customer service and Inside Sales Specialists

1,250

Approximate number of R&D colleagues

When horses live well, we live better.

We're always by your side.

Scan to contact customer service for answers and support.



Qei

IMPORTANT SAFETY INFORMATION

DORMOSEDAN[®] **STERILE SOLUTION (detomidine hydrochloride):** Do not use DORMOSEDAN STERILE SOLUTION in horses with pre-existing atrioventricular (AV) or sinoatrial (SA) block, with severe coronary insufficiency, cerebrovascular disease, respiratory disease, or chronic renal failure. Intravenous potentiated sulfonamides should not be used in anesthetized or sedated horses. Careful consideration should be given to horses approaching or in endotoxic or traumatic shock, to horses with advanced liver or kidney disease, or to horses under stress from extreme heat, cold, fatigue, or high altitude. Do not use in horses intended for human consumption. Handle dosing syringes with caution to avoid direct exposure to skin, eyes or mouth. See full Prescribing Information attached.

DORMOSEDAN GEL[®] (detomidine hydrochloride): Do not use DORMOSEDAN GEL in horses with pre-existing atrioventricular (AV) or sinoatrial (SA) block, with severe coronary insufficiency, cerebrovascular disease, respiratory disease, or chronic renal failure. Do not use in anesthetized or sedated horses, or in conditions of shock, severe debilitation or stress due to extreme heat, cold, fatigue or high altitude. Do not use in horses intended for human consumption. Handle gel-dosing syringes with caution to avoid direct exposure to skin, eyes or mouth. See full Prescribing Information attached.

EXCEDE[®] (ceftiofur crystalline free acid): People with known hypersensitivity to penicillin or cephalosporins should avoid exposure to EXCEDE. EXCEDE is contraindicated in animals with known allergy to ceftiofur or the β-lactam group (penicillins and cephalosporins) of antimicrobials. Do not use in horses intended for human consumption. The administration of antimicrobials in horses under conditions of stress may be associated with diarrhea, which may require appropriate veterinary therapy. In cattle, inadvertent intra-arterial injection is possible and fatal. Do not use in calves to be processed for veal. Pre-slaughter withdrawal time in cattle is 13 days. See full Prescribing Information attached.

Do not use **QUEST**[®] **Gel** or **QUEST PLUS Gel** in foals less than 6 months of age or in sick, debilitated and underweight horses. Do not use in other animal species, as severe adverse reactions, including fatalities in dogs, may result. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

¹ Data on file, 2020 Pain & Sedation Market Research Study

² Data on file, Animalytix Segment Data, Equine Vaccines, MAT Sept 2021.

³ AAEP 2019 Parasite Control Guidelines. American Association of Equine Practitioners website. https://aaep.org/guidelines/parasite-control-guidelines. ⁴ Bertone, Ishihara, Zekas, Wellman, Lewis, Schwarze, Barnaba, Schmall, Kanter, Genovese, et. al. Evaluation of a single intra-articular injection of autologous protein solution for treatment of osteoarthritis in horses. American Journal of Veterinary Research. Feb 2014.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. Stablelab is a registered trademark of Epona Biotech Limited, used under license. i-STAT and Alinity are trademarks of the Abbott Group of Companies in various jurisdictions. VETSCAN is a registered trademark of Abaxis, Inc.





(detomidine hydrochloride) Alpha₂-agonist oromucosal gel **Rx only** For Sedation and Restraint in Horses Only

CAUTION:

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION:

DORMOSEDAN (detomidine hydrochloride) GEL is a synthetic alpha₂-adrenoreceptor agonist with sedative properties. Each mL of DORMOSEDAN GEL contains 7.6 mg detomidine hydrochloride. The chemical name is 1H imidazole, 4-[(2,3-dimethylphenyl) methyl]-hydrochloride. Detomidine hydrochloride is a white, crystalline, water-soluble substance having a molecular weight of 222.7. The molecular formula is $C_{12}H_{14}N_2$ +HCl and the structural formula is



INDICATIONS:

DORMOSEDAN GEL is indicated for sedation and restraint in horses.

DOSAGE AND ADMINISTRATION:

DORMOSEDAN GEL produces sedation when administered sublingually at 0.018 mg/lb (0.040 mg/kg). DORMOSEDAN GEL must be placed beneath the tongue of the horse and is not meant to be swallowed. The dosing syringe delivers the product in 0.25 mL increments. The following dosing table may be used to determine the correct dose of DORMOSEDAN GEL (Table 1). Table 1: Sublingual dosing of DORMOSEDAN GEL

Approximate body weight (Ib)	Range of doses (mg/lb)	Approximate body weight (kg)	Range of doses (mg/kg)	Dose volume (mL)
330 - 439	0.023 - 0.017	150 - 199	0.051 - 0.038	1.00
440 - 549	0.022 - 0.017	200 - 249	0.047 - 0.038	1.25
550 - 659	0.021 - 0.017	250 - 299	0.046 - 0.038	1.50
660 - 769	0.020 - 0.017	300 - 349	0.044 - 0.038	1.75
770 - 879	0.019 - 0.017	350 - 399	0.043 - 0.038	2.00
880 - 989	0.019 - 0.017	400 - 449	0.043 - 0.038	2.25
990 - 1099	0.019 - 0.017	450 - 499	0.042 - 0.038	2.50
1100 - 1209	0.019 - 0.017	500 - 549	0.042 - 0.038	2.75
1210 - 1320	0.019 - 0.017	550 - 600	0.041 - 0.038	3.00

Use impermeable gloves when handling the product. Remove the syringe from the outer carton. While holding the plunger, turn the ring-stop on the plunger until the ring is able to slide freely up and down the plunger. Position the ring in such a way that the side nearest the barrel is at the desired volume marking. Turn the ring to secure it in place. Make sure that the horse's mouth contains no feed. Remove the cap from the tip of the syringe and save for cap replacement. Insert the syringe tip into the horse's mouth from the side of the mouth, placing the syringe tip beneath the tongue at the level of the commisure of the mouth. Depress the plunger until the ring-stop contacts the barrel, depositing the product beneath the tongue.

The following picture demonstrates correct administration of DORMOSEDAN GEL beneath the tongue.



Take the syringe out of the horse's mouth, recap the syringe and return it to the outer carton for disposal. Remove gloves for disposal.

For the best results, allow adequate time (a minimum of 40 minutes) between administration of DORMOSEDAN GEL and beginning the procedure. In general, horses show sedative effects lasting approximately 90-180 minutes.

Withhold food and water until the sedative effects of the product wear off.

CONTRAINDICATIONS:

DORMOSEDAN GEL is contraindicated in horses with known hypersensitivity to detormidine. Intravenous potentiated sulfonamides should not be used in anesthetized or sedated horses as potentially fatal dysrhythmias may occur.

Do not use DORMOSEDAN GEL in horses with pre-existing atrioventricular (AV) or sino-atrial (SA) blocks, respiratory disease, or chronic renal failure.

WARNINGS:

For sublingual use in horses only. Do not use in horses intended for human consumption.

HUMAN WARNINGS: Not for human use. Keep out of the reach of children. Use impermeable gloves during drug administration and during procedures that require contact with the horse's mouth. Following sublingual administration of detomidine oromucosal gel, drug concentrations up to 0.072 mg/mL were measured at 30 minutes post dose in equine saliva, equivalent to less than one percent of the original detomidine concentration in the gel. Mean drug concentrations fall to less than 0.010 mg/mL by 2 hours after drug administration, after which a slow decline occurs for several additional hours.

DORMOSEDAN GEL can be absorbed following direct exposure to skin, eyes, or mouth, and may cause irritation. Skin and mucosal contact with the product should be avoided. Use impermeable gloves at all times.

In case of accidental eye exposure, rinse abundantly with fresh water. In case of accidental skin exposure, wash with soap and water. Remove contaminated clothing.

Appropriate precautions should be taken while handling and using gel syringes. Accidental exposure could cause adverse reactions, including sedation, hypotension, and bradycardia. Seek medical attention immediately but do not drive because sedation or changes in blood pressure may occur.

Individuals with cardiovascular disease (for example, hypertension or ischemic heart disease) should take special precautions to avoid exposure to this product.

Caution should be exercised when handling sedated horses. Handling or any other sudden stimuli, including noise, may cause a defense reaction in an animal that appears to be heavily sedated.

Rare cases of human abuse of detomidine products have been reported. DORMOSEDAN GEL should be managed to prevent the risk of diversion, through such measures as restriction of access and the use of drug accountability procedures appropriate to the clinical setting.

The material safety data sheet (MSDS) contains more detailed occupational safety information. To report adverse reactions in users or to obtain a copy of the MSDS for this product call 1-888-963-8471.

Note to physician: This product contains an alpha₂-adrenoceptor agonist.

PRECAUTIONS:

DORMOSEDAN GEL must be placed beneath the tongue of the horse. Unlike most oral veterinary products, this product is not meant to be swallowed. Swallowing could result in ineffectiveness.

DORMOSEDAN GEL does not provide analgesia. Do not use for painful procedures.

Do not use with other sedative drugs because the effects may be additive.

Repeat dosing has not been evaluated.

The use of an $alpha_2$ -agonist reversal agent with DORMOSEDAN GEL has not been evaluated.

Before initiating any procedure, allow sedation to fully develop. Nervous or excited horses with high levels of endogenous catecholamines may exhibit a reduced pharmacological response to alpha₂-adrenoceptor agonists like detomidine. In agitated horses, the onset of sedative effects could be slowed, or the depth and duration of effects could be diminished or nonexistent. When the product is administered, the animal should be allowed to rest in a quiet place for a minimum of 40 minutes.

Do not use DORMOSEDAN GEL in horses with cardiovascular disease, respiratory disorders, liver or kidney diseases, or in conditions of shock, severe debilitation, or stress due to extreme heat, cold, fatigue, or high altitude. Protect treated horses from temperature extremes. As with all alpha₂-adrenoceptor agonists, the potential for isolated cases of hypersensitivity, including paradoxical response (excitation), exists.

DORMOSEDAN GEL has not been evaluated in ponies, miniature horses, or horses younger than one year of age.

DORMOSEDAN GEL has not been evaluated for use in breeding, pregnant, or lactating horses.

ADVERSE REACTIONS:

Clinical field study:

In a US field study of 270 horses sedated to facilitate completion of various veterinary and husbandry procedures, the following adverse reactions were reported in 202 horses treated with DORMOSEDAN GEL and 68 horses treated with placebo:

Table 2: Adverse reactions (number of horses) during the clinical field study

Clinical Sign	DORMOSEDAN GEL N = 202	Placebo N =68
Sweating	20	0
Penile relaxation	12	0
Bradycardia (≤ 20 bpm)	11	0
Second degree AV block	9	0
Frequent urination	9	0
Piloerection	4	0
Marked ataxia	3	0
Facial/oral edema	3	0
Hypersalivation	2	0
Nasal discharge	2	0
Flatulence	1	0
Muscle tremors	1	1
Epiphora	1	0
Pale mucous membranes	1	0
Swollen sheath	1	0

In a laboratory study, transient erythema of the mucous membranes was seen in 2 (of 8) horses that received the recommended dose of detomidine gel.

Mild ataxia (horse stable but swaying slightly) was observed in 54% of DORMOSEDAN GEL-treated horses and in 4% of the placebotreated horses at 40 minutes post treatment administration. Moderate ataxia was observed in 25% of DORMOSEDAN GEL-treated horses (0% placebo) at 40 minutes post treatment. Moderate to marked ataxia continued to 90 minutes for 5% and to 120 minutes for 4% of DORMOSEDAN GEL-treated horses.

CLINICAL PHARMACOLOGY:

Detomidine is a potent non-narcotic alpha2-adrenoceptor agonist which produces sedation with a central effect inhibiting the transmission of noradrenalin-mediated nervous impulses. Blood pressure is initially increased due to peripheral vasoconstriction, subsequently dropping to normal or slightly below normal levels. Vasoconstriction may cause mucous membranes to appear pale or mildly cyanotic. This initial vasopressor response is accompanied by a compensatory marked decrease in heart rate mediated by a vagal baroreceptor. The peripheral pulse may feel weak and a transient change in the conductivity of the cardiac muscle may occur, as evidenced by first and second degree atrioventricular blocks. Other arrhythmias may occur. Detomidine also decreases the respiratory rate and decreases body temperature. Detomidine causes depression of gastrointestinal motility due to decrease in smooth muscle activity, increases blood glucose levels due to inhibition of insulin release, and increases production of urine 2 to 4 hours after treatment. In some horses, sweating, salivation and slight muscle tremors may be seen. Partial, transient penis prolapse may occur in stallions and geldings. Because of continued lowering of the head during sedation, mucus discharges from the nose with occasional swelling of the head, particularly around the eyes, may be seen.

Detomidine is oxidized mainly in the liver. Most metabolites are excreted in the urine. Halflife (T½) is 1-2 hours. Detomidine is rapidly distributed; volume of distribution (Vd) varies between 0.69 L/kg and 1.89 L/kg. Protein binding is about 85%.

Detomidine is a high extraction ratio drug. Alterations in liver blood flow (the site of detomidine metabolism) can change the rate of drug clearance and, consequently, drug exposure. The sedative effects of detomidine (using head droop as a marker for sedation) are highly correlated to blood concentration, regardless of the route of administration.

First pass effect results in a very small portion of drug reaching the systemic circulation if it is swallowed. Sedation achieved with the DORMOSEDAN GEL is attributable to sublingual drug absorption. Peak concentrations occur approximately 1.83 hours after sublingual administration of DORMOSEDAN GEL. The peak concentrations observed after administration of DORMOSEDAN GEL are approximately 40% of those observed after intramuscular injection of detomidine solution. The absolute bioavailability of detomidine in DORMOSEDAN GEL is 22%.

EFFECTIVENESS:

A prospective, randomized, masked, multi-center study was conducted to evaluate under field conditions, whether DORMOSEDAN GEL provided sufficient sedation and restraint in horses to successfully conduct procedures requiring administration of a sedative. Two hundred and seventy client-owned horses of any breed or sex were sedated to facilitate grooming (including cleaning of the prepuce), hoof care, floating teeth (manually), passage of a nasogastric tube or endoscope, or radiography. Horses were enrolled in the study if they were a yearling or older, in satisfactory body condition, and had a history of requiring sedation or other means of strong restraint to enable similar procedures to be carried out. Horses were randomly assigned to receive DORMOSEDAN GEL sublingually at 0.040 mg/kg or placebo gel.

After administration of treatment, each horse's level of sedation, degree of ataxia, heart rate and rhythm, and respiratory rate were assessed and measured to recovery. After an appropriate period of time elapsed to allow sedation to develop, a study veterinarian assessed and scored the ability to attempt and to complete the veterinary or husbandry procedure.

One hundred and twenty-nine DORMOSEDAN GEL-treated and 42 placebo-treated horses were included in the statistical analysis of effectiveness. Ninety-nine horses were excluded from the analysis due to failure to meet inclusion criteria or due to major protocol deviations. The veterinary or husbandry procedure was successfully completed for 98 of 129 DORMOSEDAN GEL-treated horses (76%) but only 3 of 42 placebo-treated horses (7%) (Table 3). The difference between the two treatments was statistically significant (p=0.0005).

Table 3: Treatment success rates (number of horses) by treatment group

Ability to perform the procedure score*	DORMOSEDAN GEL N=129	Placebo N=42
0	16	38
1	15	1
2	44	2
3	54	1
Success (score 2 or 3)	98	3

* 0: Poor - Strong resistance. 1: Fair. Moderate resistance. 2: Good. Some resistance, but the procedure could be performed. 3: Excellent. Procedure could be easily performed with insignificant resistance.

The following success rates with DORMOSEDAN GEL were recorded for electric clipping of hair (48%), cleaning the prepuce (81%), manual floating of teeth (89%), hoof trimming or shoeing (86%), passage of a nasogastric tube or endoscope (80%), or radiography (74%). At 40 minutes post dosing, 94% of DORMOSEDAN GEL-treated horses showed minimal, moderate or marked sedation compared with 14% of the horses treated with placebo. All DORMOSEDAN GEL-treated horses had recovered from sedation by 240 minutes post treatment.

DORMOSEDAN GEL was correctly administered sublingually (beneath the tongue) in 97\% of horses with mild or no objection.

ANIMAL SAFETY:

In a multiple dose target animal safety study, DORMOSEDAN GEL was administered on three consecutive days to 6 horses per treatment group at 0, 1, 3 and 5 times the recommended label dose of 0.040 mg/kg.

The recommended dose (1X) induced sedation. Head droop caused transient edema of the head area, nasal/ocular discharge, and congestion of oral mucous membranes. Ataxia, sweating, and reversible penile prolapse were observed. Erythematous mucous membranes were seen at the area of dose application in 2/6 horses. Transient reductions were seen in heart rate, respiratory rate, and gut motility. Electrocardiography revealed increased incidences of vagally mediated arrhythmias (sinus arrhythmia, sinus block, 1st and 2nd degree atrioventricular block) as well as atrial or ventricular premature beats in the majority of horses. No clinical abnormalities were associated with the transient arrhythmias. Excessive or erratic urination were seen in isolated cases

Similar treatment related findings were seen in horses receiving 3X and 5X doses. In most cases the incidence, severity, and duration of the findings were dose dependent. All findings in all dose groups were representative of the alpha2-adrenoreceptor drugs used in horses.

STORAGE INFORMATION:

Store at controlled room temperature 20-25°C (68-77°F), with excursions permitted to 15-30°C (59-86°F), in the original package.

HOW SUPPLIED:

3.0 mL graduated oral dosing syringe, 7.6 mg/mL detomidine hydrochloride.

DORMOSEDAN® is a trademark of Orion Corporation.







Orion Corporation





Kalamazoo, MI 49007

Made in Finland Date: January 2013

CLIENT INFORMATION SHEET FOR OWNER/HANDLER USE AND SAFETY:

This summary contains important information about Dormosedan Gel. You should read this information before you administer Dormosedan Gel to your horse. This sheet is provided only as a summary and does not take the place of instructions from your veterinarian. Talk to your veterinarian if you do not understand any of this information or if you want to know more about Dormosedan Gel.

What is Dormosedan Gel?

Dormosedan Gel is an oromucosal sedative containing detomidine hydrochloride. It is prescribed by veterinarians to allow procedures to be done in an anxious horse. Dormosedan Gel has not been shown to provide analgesia and should not be used for painful procedures.

How should the product be handled?

Always wear impermeable gloves when handling the dosing syringe with detomidine hydrochloride gel. Ask the veterinarian whether the gloves you plan to use are impermeable. For a minimum of 2 hours after administration, wear impermeable gloves when performing any tasks that require contact with the horse's mouth.

If you have or have had a history of cardiovascular disease (for example, hypertension or heart attack) take special precautions and avoid direct exposure to the dosing syringe. Do not come in contact with the mouth or any saliva of any horse that was treated with detomidine gel for a minimum of 2 hours.

What if I get the gel in my eyes or mouth?

Detomidine hydrochloride can be absorbed into your body after direct exposure through the eyes or mouth, and may cause irritation to these areas. In case of accidental eye exposure, flush with water for 15 minutes. If detomidine is exposed to the mucous membranes of the mouth, rinse without swallowing. In all cases of accidental exposure and possible ingestion, seek medical attention immediately. Accidental exposure could result in the drug affecting you, causing symptoms that include sleepiness, low blood pressure, and slower heart rate. DO NOT DRIVE because detomidine may cause you to feel drowsy or sleepy. Share the package information with your physician and tell the physician that the product contains an $alpha_2\text{-}$ adrenoceptor agonist.

What if I get the gel on my skin?

Detomidine hydrochloride can be absorbed into your body after direct exposure through the skin. In case of accidental skin exposure, wash with soap and water. Remove contaminated clothing. Contact your physician if you have any questions or concerns.

The material safety data sheet (MSDS) contains more detailed occupational safety information. To report adverse reactions in humans or horses or to obtain an MSDS for this product call -888-963-8471.

How is Dormosedan Gel administered?

Dormosedan Gel should be given according to your veterinarian's instructions. Your veterinarian will tell you what amount of gel you should give to your horse. The appropriate dose is delivered beneath the tongue (sublingually) and is not meant to be swallowed. Make sure there is no food in the horse's mouth prior to administration.

The following drawing demonstrates correct administration of Dormosedan Gel beneath the tongue.

Following appropriate dosing of the gel, your horse should be kept in a quiet area until sedation is achieved.

If after 40 minutes there is inadequate sedation and you suspect that the horse swallowed or spit out some of the gel, contact your prescribing veterinarian. Do not repeat the dose

If you believe the correct dose of detomidine gel was administered but the horse remains inadequately sedated, contact the prescribing veterinarian. Do not repeat the dose.

Contact your prescribing veterinarian immediately if the dosing syringe fails during the administration of detomidine gel and you are unsure if too much or too little of the dose was given.

Do not re-use partial dosing syringes. Any unused product or waste material should be disposed of in accordance with local requirements and Federal prescription drug disposal guidelines. Ask your veterinarian for this information.

What should I expect after administering Dormosedan Gel?

Following appropriate dosing of the gel, your horse should be kept in a quiet area. As the drug takes effect, you will typically see the head lower and the front legs plant in a firm stance. This will usually take about 40 minutes. You may also notice slight swaying, sweating, salivation and slight muscle tremors. Be careful when handling sedated horses. Handling or any other sudden stimuli, including noise, may cause a defense reaction (for example, kicking) even in a horse that appears to be fully sedated. It may take up to 3-4 hours for the horse to recover from sedation. Withhold food and water until the horse has recovered.

What else should I know about Dormosedan Gel?

As with all prescribed medicines, Dormosedan Gel should only be given to the horse for which it was prescribed. This sheet provides a summary of information about Dormosedan Gel. If you have any questions or concerns about Dormosedan Gel or its effects on your horse or yourself, talk to your veterinarian.





Sedative and Analgesic For Use in Horses Only

Sterile Solution 10 mg/mL

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION: Dormosedan® is a synthetic alpha-2 adrenoreceptor agonist with sedative and analgesic properties. The chemical name is 1H imidately, 4+[2,3-dimethylphenyl) methyl hydrochiode and the generic name is detomidine hydrochloride. It is a white, crystalline, water-soluble substance having a molecular weight of 222.7. The molecular formula is $C_{12}H_{14}N_2$ +HCl.

CHEMICAL STRUCTURE:



Each mL of Dormosedan® contains 10.0 mg detomidine hydrochloride, 1.0 mg methyl paraben, 5.9 mg sodium chloride, and water for injection, q.s

CLINICAL PHARMACOLOGY: Dormosedan®, a non-narcotic sedative and analogsic, is a potent or advence of the second sensitivity to environmental stimuli (sounds, etc.) are seen with detomidine. A short period of incoordination is characteristically followed by immobility and a firm stance with front legs well spread. The analgesic effect is most readily seen as an increase in the pain threshold at the body surface. Sensitivity to touch is little affected and in some cases may actually be enhanced.

With detomidine administration, heart rate is markedly decreased, blood pressure is initially elevated, and then a steady decline to normal is seen. A transient change in the conductivity of the cardiac muscle may occur, as evidenced by partial atrioventricular (AV) and sinoauricular (SA) blocks. This change in the conductivity of the cardiac muscle may be prevented by IV administration of atropine at 0.02 mg/kg of body weight.

No effect on blood clotting time or other hematological parameters was encountered at dosages of 20 or 40 mcg/kg of body weight. Respiratory responses include an initial slowing of respiration within a few seconds to 1–2 minutes after administration, increasing to normal within 5 minutes. An initial decrease in tidal volume is followed by an increase.

INDICATIONS: Dormosedan® is indicated for use as a sedative and analgesic to facilitate minor surgical and diagnostic procedures in mature horses and yearlings. It has been used successfully for the following: to calm fractious horses, to provide relief from abdominal pain, to facilitate bronchoscopy, bronchoalveolar lavage, nasogastric intubation, nonreproductive rectal palpations, suturing of skin lacerations, and castrations. Additionally, an approved, local infiltration anesthetic is indicated for castration.

CONTRAINDICATIONS: Dormosedan® should not be used in horses with pre-existing AV or SA block, with severe coronary insufficiency, cerebrovascular disease, respiratory disease, or chronic renal failure. Intravenous potentiated sulfonamides should not be used in anesthetized or sedated horses as potentially fatal dysrhythmias may occur.

Information on the possible effects of detomidine hydrochloride in breeding horses is limited to uncontrolled clinical reports; therefore, this drug is not recommended for use in breeding animals.



HUMAN SAFETY INFORMATION: Care should be taken to assure that detomidine hydrochloride is not inadvertently ingested as safety studies have indicated that the drug is well absorbed when administered orally. Standard ocular irritation tests in rabbits using the proposed market formulation have shown detomidine hydrochloride to be nonirritating to eyes. Primary dermal irritation tests in guinea pigs using up to 5 times the proposed market concentration of detomidine hydrochloride on intact and abraded skin have demonstrated that the drug is nonirritating to skin and is apparently poorly absorbed dermally. However, in accordance with prudent clinical procedures, exposure of eyes or skin should be avoided and affected areas should be washed immediately if exposure does occur. As with all injectable drugs causing profound physiological effects, routine precautions should be employed by practitioners when handling and using loaded syringes to prevent accidental self-injection

PRECAUTIONS: Before administration, careful consideration should be given to administering Dormosedan® to horses approaching or in endotoxic or traumatic shock, to horses with advanced liver or kiney disease, or to horses under stress from extreme heat, cold, fatigue, or high altitude. Protect treated horses from temperature extremes. Some horses, although apparently deeply sedated, may still respond to external stimuli, Routine safety

107224US-10A&P

measures should be employed to protect practitioners and handlers. Allowing the horse to stand quietly for 5 minutes before administration and for 10–15 minutes after injection may improve the response to Dormosedan®

 $Dormosedan \circledast is a potent \, \alpha_2 \text{-} agonist, \, and \, extreme \, caution \, should \, be \, exercised \, in \, its \, use \, with \, other \, sedative \, or \, agonist, \, and \, extreme \, caution \, should \, be \, exercised \, in \, its \, use \, with \, other \, sedative \, or \, agonist, \, and \, extreme \, caution \, should \, be \, exercised \, in \, its \, use \, with \, other \, sedative \, or \, agonist, \, agonist, \, and \, extreme \, caution \, should \, be \, exercised \, in \, its \, use \, with \, other \, sedative \, or \, agonist, \, ag$ analgesic drugs for they may produce additive effects

When using any analgesic to help alleviate abdominal pain, a complete physical examination and diagnostic work-up are necessary to determine the etiology of the pain.

Food and water should be withheld until the sedative effect of Dormosedan® has worn off

ADVERSE REACTIONS: Occasional reports of anaphylactic-like reactions have been received, including 1 or more of the following: untricaria, skin plaques, dyspnea, edema of the upper airways, trembling, recumbency, and death. The use of epinephrine should be avoided since epinephrine may potentiate the effects of α_{z} -agonists. Reports of mild adverse reactions have resolved uneventfully without treatment. Severe adverse reactions should be treated symptomatically. As with all α_2 -agonists, the potential for isolated cases of hypersensitivity exist including paradoxical response (excitation).

SIDE EFFECTS: Horses treated with Dormosedan® exhibit hypertension. Bradycardia routinely occurs 1 minute after injection. The relationship between hypertension and bradycardia is consistent with an adaptive baroreceptor response to the increased pressure and inconsistent with a primary drug-induced bradycardia Pilocrection, sweating, salivation, and slight muscle tremors are frequently seen after administration. Partial transient penis prolapse may be seen. Partial AV and SA blocks may occur with decreased heart and respiratory rates. Urination typically occurs during recovery at about 45–60 minutes posttreatment, depending on dosage. Incoordination or staggering is usually seen only during the first 3-5 minutes after injection, until animals have secured a firm footing.

Because of continued lowering of the head during sedation, mucus discharges from the nose and, occasionally, edema of the head and face may be seen. Holding the head in a slightly elevated position generally prevents these effects.

OVERDOSAGE: Detomidine hydrochloride is tolerated in horses at up to 200 mcg/kg of body weight (10 times the low dosage and 5 times the high dosage). In safety studies in horses, detomidine hydrochloride at 400 mcg/kg of body weight administered daily for 3 consecutive days produced microscopic foci of myocardial necrosis in 1 of 8 horses

DOSAGE AND ADMINISTRATION:

For Sedation: Administer Dormosedan® IV or IM at the rates of 20 or 40 mcg detomidine hydrochloride per kg of body weight (0.2 or 0.4 mL of Dormosedan® per 100 kg or 220 lb), depending on the depth and duration of sedation required, Onset of sedative effects should be reached within 2–4 minutes after IV administration and 3–5 minutes after IM administration. Twenty mcg/kg will provide 30–90 minutes of sedation and 40 mcg/kg will provide approximately 90 minutes to 2 hours of sedation.

For Analgesia: Administer Dormosedan® IV at the rates of 20 or 40 mcg detomidine hydrochloride per kg of body weight (0.2 or 0.4 mL of Dormosedan® per 100 kg or 220 lb), depending on the depth and duration of analgesia requirad, Twenty mcg/kg will usually begin to take effect in 2-4 minutes and provide 30-45 minutes of analgesia. The 40 mcg/kg does will also begin to take effect in 2-4 minutes and provide 45-75 minutes of analgesia.

For Both Sedation and Analgesia: Administer Dormosedan® IV at the rates of 20 or 40 mcg detomidine hydrochloride per kg of body weight (0.2 or 0.4 mL of Dormosedan® per 100 kg or 220 lb), depending on the depth and duration of sedation and analgesia required.

nd after injection, the animal should be allowed to rest quietly.

STORAGE: Store at controlled room temperature 15°-30°C (59°-86°F) in the absence of light.

HOW SUPPLIED: Dormosedan® is supplied in 5- and 20-mL multidose vials.

NADA #140-862, Approved by FDA





Revised: January 2013

107224US-10A&P Made in Finland



For intramuscular injection in the horse.

CAUTION

Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits extra-label use of this drug in cattle for disease prevention purposes; at unapproved doses, frequencies, durations, or routes of administration; and in unapproved major food producing species/production classes.

DESCRIPTION

EXCEDE Sterile Suspension is a ready-to-use formulation that contains the crystalline free acid of ceftiofur, which is a broad spectrum cephalosporin antibiotic active against Grampositive and Gram-negative bacteria including ß-lactamase-producing strains. Like other cephalosporins, ceftiofur is bactericidal, *in vitro*, resulting from inhibition of cell wall synthesis.

Each mL of this ready-to-use sterile suspension contains ceftiofur crystalline free acid equivalent to 200 mg ceftiofur, in a caprylic/capric triglyceride and cottonseed oil based suspension.

Figure 1. Structure of ceftiofur crystalline free acid:

Chemical name of ceftiofur crystalline free acid:

7-[[2-(2-Amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]- 3-[[(2-furanylcarbonyl)thio]methyl]-8-oxo-5-thia-1- azabicyclo[4.2.0]oct-2-ene 2-carboxylic acid

INDICATION

EXCEDE Sterile Suspension is indicated for the treatment of lower respiratory tract infections in horses caused by susceptible strains of *Streptococcus equi* ssp. *zooepidemicus*.

DOSAGE AND ADMINISTRATION

Shake well before using.

Administer two intramuscular injections to horses, 4 days apart, at a dose of 3.0 mg/lb (6.6 mg/kg). A maximum of 20 mL per injection site may be administered. Therapeutic drug concentrations are maintained for 6 days after the second injection (or a total of 10 days from the beginning of treatment) against *Streptococcus equi* ssp. *zooepidemicus*.

Table 1. Dosing Schedule for EXCEDE Sterile Suspension.

		-		
Weight (lb)	Dose Volume (mL)		Weight (lb)	Dose Volume (mL)
100	1.5		1100	16.5
200	3.0		1200	18.0
300	4.5		1300	19.5
400	6.0		1400	21.0
500	7.5		1500	22.5
600	9.0		1600	24.0
700	10.5		1700	25.5
800	12.0		1800	27.0
900	13.5		1900	28.5
1000	15.0		2000	30.0

CONTRAINDICATIONS

EXCEDE Sterile Suspension is contraindicated in horses with known allergy to ceftiofur or to ß-lactam (penicillins and cephalosporins) group antimicrobials. Due to the extended exposure in horses, based on the drug's pharmacokinetic properties, adverse reactions may require prolonged care.

Warnings and Precautions

Do not use in horses intended for human consumption.

Human Safety Warnings

Not for use in humans. For use in animals only. Keep this and all drugs out of reach of children.

Consult a physician in case of accidental human exposure. Penicillins and cephalosporins can cause allergic reactions in sensitized individuals. Topical exposure to such antimicrobials, including ceftiofur, may elicit mild to severe allergic reactions in some individuals. Repeated or prolonged exposure may lead to sensitization. Avoid direct contact of the product with the skin, eyes, mouth and clothing. Sensitization of the skin may be avoided by wearing protective gloves. Persons with a known sensitivity to penicillin or cephalosporins should avoid exposure to this product. In the case of accidental eye exposure, flush with water for 15 minutes. In case of accidental skin exposure, wash with soap and water. Remove contaminated clothing. If allergic reaction occurs (e.g. skin rash, hives, difficult breathing) seek medical attention.

Animal Safety Warnings and Precautions

Immediate onset of seizures or collapse have been reported following $\ensuremath{\mathsf{Excede}}$ administration.

The injection of EXCEDE Sterile Suspension in the horse may cause firmness, swelling, sensitivity, and/or edema at the injection site.

Injection site reactions may be extensive and require veterinary care.

The administration of antimicrobials to horses under conditions of stress may be associated with acute diarrhea that can be fatal. If acute diarrhea is observed, additional doses of EXCEDE should not be administered and appropriate therapy should be initiated.

Due to the extended exposure in horses, based on the drug's pharmacokinetic properties, adverse reactions may require prolonged care. EXCEDE is slowly eliminated from the body, with approximately 17 days needed to eliminate 97% of the dose from the body. Animals experiencing adverse reactions may need to be monitored for this duration of time.

The use of ceftiofur has not been evaluated in horses less than 4 months of age and in breeding, pregnant, or lactating horses. The long term effects on injection sites have not been evaluated.

(See Animal Safety and Post Approval Experience sections)

Antibacterial Warnings

Use of antibacterial drugs in the absence of a susceptible bacterial infection is unlikely to provide benefit to treated animals and may increase the risk of the development of drug-resistant bacteria.

ADVERSE REACTIONS

Pre-Approval Experience:

A total of 373 horses of various breeds, ranging in age from 4 months to 20 years, were included in the field study safety analysis. Adverse reactions reported in horses treated with EXCEDE and the placebo control are summarized in Table 2.

Injection site swelling (edema) was reported in 10 of 278 (3.6%) EXCEDE-treated horses and 1 of 95 (1%) of the placebo-treated horses. Of the 10 EXCEDE-treated horses with injection site swelling, 8 horses had swellings of 4 cm or less in diameter, one horse had a 10 cm diameter swelling and one horse had injection site reactions to both injections measuring 25 x 12 cm each. The injection site reactions in EXCEDE treated horses resolved over 1 to 20 days.

At least one episode of diarrhea, loose, soft, or cowpie stools were observed in 25 of 278 (9%) of the EXCEDE-treated horses and 7 of 95 (7%) of the placebo-treated horses. The duration of episodes in EXCEDE-treated horses ranged from a single observation of loose stool to observations lasting 6 days. All cases were self-limiting and resolved with minimal (a single dose of loperamide) or no treatment.

Table 2. Number of Horses with Adverse Reactions During the Field Study with EXCEDE.

Adverse Reaction	EXCEDE (n=278)	Placebo (n=95)	
Diarrhea/Soft Stool	25 (9%)	7 (7%)	
Injection Site Swelling	10 (4%)	1 (1%)	

Post Approval Experience (2019):

The following adverse events are based on post-approval adverse drug experience reporting for Excede. Not all adverse events are reported to FDA/CVM. It is not always possible to reliably estimate the adverse event frequency or establish a causal relationship to product exposure using these data.

The following adverse events for horses are listed in decreasing order by system and decreasing order within system classes.

Injection site reactions: swelling, pain, inflammation, infection, necrosis, muscle stiffness, fibrosis, injection site stiffness/ reluctance to move, hair change, lameness, granuloma.

Systemic: fever, lethargy, edema at locations other than injection site, anorexia.

Gastrointestinal: colic, diarrhea.

Neurologic: ataxia, muscle tremor, seizure, loss of consciousness.

Immune (Allergic reactions): anaphylaxis, urticaria, allergic edema (face, face and neck, lip, or limb edema).

In some cases, death has been reported as an outcome of the adverse events listed above. Sudden death (within minutes), or the immediate onset of seizures or collapse, followed by death or euthanasia, have been reported.

To report suspected adverse events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS) contact Zoetis, Inc. at (888) 963-8471. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at http://www.fda.gov/reportanimalae.

CLINICAL PHARMACOLOGY

Ceftiofur is a beta-lactam antibiotic from the cephalosporin class. Beta lactams exert their inhibitory effect by interfering with bacterial cell wall synthesis. This interference is primarily due to its covalent binding to the penicillin-binding proteins, which are essential for synthesis of the bacterial wall. Ceftiofur administered as either ceftiofur sodium (NAXCEL[®] Sterile Powder) or ceftiofur crystalline free acid (EXCEDE Sterile Suspension) is rapidly metabolized to desfuroylceftiofur, the primary metabolite with antimicrobial activity. Two intramuscular injections of EXCEDE Sterile Suspension at a dose of 6.6 mg/kg body weight in the horse provide concentrations of ceftiofur and desfuroylceftiofur related metabolites in plasma above the therapeutic target of 0.2 µg/mL for the entire 96 hour (4 day) dosing interval and for 6 days after the second injection (or a total of 10 days from the beginning of treatment) (see Figure 2 and Table 3).

Figure 2. Average plasma concentration of ceftiofur and desfuroylceftiofur related metabolites in horses following the intramuscular administration of either EXCEDE Sterile Suspension at a dose of 3.0 mg/lb (6.6 mg/kg) administered twice at a 96 hour interval or NAXCEL Sterile Powder at a dose of 1.0 mg/lb (2.2 mg/kg BW) once daily for 10 consecutive days.



Table 3. Pharmacokinetic parameters measured after either two intramuscular injections of EXCEDE Sterile Suspension at a dose of 3.0 mg/lb (6.6 mg/kg) BW at a 96 hour interval or NAXCEL Sterile Powder at a dose of 1.0 mg/lb (2.2 mg/kg) BW once daily for 10 consecutive days are summarized in the following table.

PK Parameter	CCFA-SS at 6 administere apart (Mean	.6 mg/kg BW d twice 96 h ± SD; n=12)	Ceftiofur sodiu BW once dai (Mean ±	ım at 2.2 mg/kg ly for 10 days SD; n=11)	
AUC _{₀-∞} (µg∙h/mL)	157 (19.1)		353 (44.9)		
t _{>0.2} (h)	262 (29.0)		ND		
	Dose 1	Dose 2	Dose 1	Dose 10	
T _{max} (h)	21.6 (5.8)	15.6 (6.3)	1.0	2.0 (3.3)	
C _{max} (μg/mL)	0.78 (0.19)	1.0 (0.24)	4.31 ± 0.78	3.99 (1.23)	

MICROBIOLOGY

Ceftiofur is a cephalosporin antibiotic. Like other ß-lactam antimicrobials, ceftiofur exerts its inhibitory effect by interfering with bacterial cell wall synthesis. This interference is primarily due to its covalent binding to the penicillin-binding proteins (PBPs) (i.e., transpeptidase and carboxypeptidase), which are essential for synthesis of the bacterial wall. Ceftiofur is not active against *Pseudomonas* spp. and enterococci.

The minimum inhibitory concentration (MIC) values for ceftiofur against label-claim pathogens isolated from lower respiratory tract infections in horses enrolled in a 2007-2008 field effectiveness study are presented in Table 4. All MICs were determined in accordance with the *Clinical and Laboratory Standards Institute* (CLSI) standards.

Table 4. Activity of EXCEDE Against Pathogens Isolated from Horses Treated With EXCEDE in Field Studies in the U.S. During 2007-2008.

Disease	Pathogen	Treatment Outcome	# of Isolates	Time of Sample Collection	MIC₅₀ µg/mL	MIC ₉₀ µg/mL	MIC Range μg/mL
Lower Respiratory	Streptococcus equi ssp.	Success	93*	Pre- Treatment	0.06	0.12	0.03-0.5
Tract Infection	zooepidemicus	Failure	42	Pre- Treatment	0.06	0.25	0.03-0.5

* One horse cultured *Staphylococcus aureus* (successfully treated) and is not represented in the table.

EFFECTIVENESS

A double masked, randomized, negative control, field study evaluated the effectiveness of two intramuscular doses of 6.6 mg/kg EXCEDE Sterile Suspension administered 4 days apart for the treatment of lower respiratory infections caused by *Streptococcus equi* ssp. *zooepidemicus* in the horse. In this study, a total of 278 horses were treated with EXCEDE, and 95 horses were treated with saline injections. One hundred ninety-three horses (136 EXCEDE and 57 saline placebo) were included in the statistical analysis. Therapeutic success was characterized by no worsening of clinical signs at Day 4, clinical improvement at Day 9, resolution of the clinical signs by Day 15, and no recurrence of clinical signs by Day 25 after initial dosing. EXCEDE was superior to the saline control. Table 5 summarizes the clinical success rates obtained 15 and 25 days after the first dose.

Table 5. Clinical success rates at Day 15 and 25.

Effectiveness parameter	EXCEDE	Saline Control	P-value
Clinical success Day 15	73.53%	38.60%	N/A
Clinical success Day 25	69.12%	31.58%	0.0215

ANIMAL SAFETY

Two studies, a target animal safety (TAS) study and a pharmacokinetic (PK) study (see **CLINICAL PHARMACOLOGY** section), were conducted to assess the safety of EXCEDE in the horse.

In the TAS study, healthy adult horses received 6 intramuscular (lateral neck) injections of EXCEDE Sterile Suspension at doses of either 3.0 (1X), 6.0 (2X) or 9.0 (3X) mg/lb with a 4 day interval between each injection. In the TAS study, there were no treatment related gastrointestinal findings for the three EXCEDE Sterile Suspension treatment groups. In the PK study, one horse treated with 6.0 mg/lb (2X) EXCEDE experienced a mild episode of colic the day after the second injection of EXCEDE. The horse recovered without treatment.

Injection sites were observed in both studies. In both studies, the largest injection volume administered was 20 mL per injection site. There were no observations of erythema, necrosis or drainage at the injection sites in these studies. Firmness, swelling, and/or sensitivity were observed in at least one injection site in all horses treated at the label dose. In the TAS study, injection site reaction measurements ranged from no measurable reaction to 16 x 33 x 1.5 cm. In the PK study, the largest area of edema associated with the injection site ranged from no detectable reaction to a 30 x 36 cm area of edema. Injection site reactions developed within 2 days of injection and resolved within 1-18 days. In the PK study, 2 horses had small areas of firmness that had not resolved at the end of the study (21 days after injection). In both studies, a greater incidence of injection site reactions occurred after the second injection, and in several horses, swelling at the injection site resolved then recurred 1-5 days later.

In the PK study, several horses developed clinical signs consistent with foot pain (stiff in the front limbs when turned in tight circles, and increased pulses and heat to the front feet). One horse in the NAXCEL group and one horse in the 6.0 mg/lb (2X) EXCEDE group were euthanized due to laminitis. Clinical signs of foot pain (stiff front limbs and increased heat and pulses in feet) affected more horses, for a longer period of time, in all EXCEDEtreated groups as compared to the NAXCEL-treated group. The study housing (multi-horse pens on concrete slabs) and diet (free choice alfalfa/grass mix and once a day pellets) may have contributed to the development of foot pain. The prevalence and severity of injection site reactions in EXCEDE-treated horses may also have contributed to the development of a stiff gait. A causal relationship between ceftiofur and foot pain could not be definitively determined.

STORAGE CONDITIONS

Store at controlled room temperature 20° to 25°C (68° to 77°F). Shake well before using. Contents should be used within 12 weeks after the first dose is removed.

HOW SUPPLIED

EXCEDE Sterile Suspension is available in the following package sizes: 100 mL vial 250 mL vial

Approved by FDA under NADA # 141-209

zoetis

Distributed by: Zoetis Inc. Kalamazoo, MI 49007

www.EXCEDE.com or call 1-888-963-8471

Revised: January 2020

40029632A&P